Thrap3tm1c(KOMP)Wtsi
Targeted Allele Detail
|
Symbol: |
Thrap3tm1c(KOMP)Wtsi |
Name: |
thyroid hormone receptor associated protein 3; targeted mutation 1c, Wellcome Trust Sanger Institute |
MGI ID: |
MGI:7522740 |
Synonyms: |
Thrap3F |
Gene: |
Thrap3 Location: Chr4:126057875-126096548 bp, - strand Genetic Position: Chr4, 60.0 cM
|
Alliance: |
Thrap3tm1c(KOMP)Wtsi page
|
IMPC: |
Thrap3 gene page |
|
Mutant Cell Line: |
EPD0814_5_G12 |
Germline Transmission: |
Earliest citation of germline transmission:
J:339439
|
Parent Cell Line: |
JM8A3.N1 (ES Cell)
|
Strain of Origin: |
C57BL/6N-Atm1Brd
|
Project Collection: |
KOMP-CSD
|
|
Allele Type: |
|
Targeted (Conditional ready) |
Mutation: |
|
Insertion
Vector: L1L2_Bact_P
|
|
|
Mutation details: The L1L2_Bact_P cassette was inserted at position 126072882 of Chromosome 4 upstream of the critical exon(s) (Build GRCm39). The cassette is composed of an FRT site followed by lacZ sequence and a loxP site. This first loxP site is followed by a neomycin resistance gene under the control of the human beta-actin promoter, SV40 polyA, a second FRT site and a second loxP site. A third loxP site is inserted downstream of the targeted exon(s) at position 126072965. The critical exon(s) is/are thus flanked by loxP sites. A "conditional ready" (floxed) allele was created by flp recombinase expression in mice carrying this allele to remove the lacZ sequence and neo selection cassette, leaving loxP sites flanking the critical exon(s). Further information on targeting strategies used for this and other IKMC alleles can be found at http://www.informatics.jax.org/mgihome/nomen/IKMC_schematics.shtml
(J:339439)
|
|
|
View phenotypes and curated references for all genotypes (concatenated display).
|
|
Mouse strains and cell lines
available from the International Mouse Strain Resource
(IMSR) |
Carrying this Mutation: |
Mouse Strains: 0 strains available
Cell Lines: 0 lines available
|
Carrying any Thrap3 Mutation: |
83 strains or lines available
|
|
Original: |
J:339439 Jang HJ, et al., Thrap3 promotes nonalcoholic fatty liver disease by suppressing AMPK-mediated autophagy. Exp Mol Med. 2023 Aug 1; |
All: |
1 reference(s) |
|